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  Eighty－eight cases of urinary bladder tumor were treated in our Department from 1976 to 1978．
The effect of so－called immunopotentiators （OK－432， Levamisole and PSK） was studied in 23 patients．
The following results were obtained．
  Pretreatment intracutaneous response to PHA was significantly lower in the high stage and high
grade group than in the low stage and low gradc group（PくO．025）． However， there was no cor－
relation between the effect of immunotherapy and PNA skin reactien．
  Of the immunoglobulins， only lgM was significantly lower in the high grade group than in the
low grade group（Pく0．025）。
  The one－year survival rate for the patients in the high stage group was higher in the patients
receiving immunotherapy than those not treated．
  This suggests that immunotherapy may be usefu1 for prolonging the survival time of patients
with advanced bladder carcinoma．
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法をTable 3に示す． OK－432は0．2 KEより順次
増量し，1．O KE～2．0 KEの隔日投与（筋注法）を維持
量：とした．Levamisoleは最初150 mg／日の隔日内服
Table 1． Stage of bladder tumors
TaTl    T2     T3     T4     葦葺
投与例 11 4  2 6 23




OK－432が3．4 KE～83．6 KE， Levamisoleが4。5 g























度に関しても10w grade群28．39±2．39， high grade
 cm
30
Table 2． Histology of bladder tumors
       TCCpapilloma    Gl G2 G3AC SCC  計 20
投与例   0
非投与例   6
2 14 7 0 O 23
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Fig． 1． PHA skin reaction of bladdeT
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Fig． 2． Changes of PHA skin reactlon in pre－
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     ＿免疫賦活剤投与例
     一一一免疫賦活剤非投与例
A low grade： sssN ”e一．一．LTX．L ． ．一一一．一〇 N X一一＋一x Nx
“．．一
    N．．．．t
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   BCG，MER（methanol extracted residue）
   Wax O， CWS，他
 2 グラム陰性菌
   Sa［mene［la， Shigera， E． coR， Seiratia，
   B．pertussis， Brucelia，内毒素
 3 グラム陽性菌
   Staphylococcus， Streptececcus，
   Corynebac量erium parvum，他
H非細菌性物質
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